Ketamine does work for bipolar depression, and the evidence is increasingly strong. In controlled trials, ketamine produced significant improvements in depressive symptoms compared to placebo in people with bipolar disorder, with effects appearing within 40 minutes of a single infusion. The response appears comparable to what’s seen in standard major depression, and a naturalistic follow-up study found response and remission rates above 78% at nine months in patients receiving repeated infusions.
How Quickly It Works
The speed of ketamine’s effect is what sets it apart from nearly every other treatment for bipolar depression. Standard mood stabilizers and antidepressants can take weeks to show results. Ketamine begins reducing depressive symptoms within 40 minutes of an intravenous infusion. In two randomized, placebo-controlled crossover studies of patients with treatment-resistant bipolar depression (used alongside mood stabilizers), ketamine significantly outperformed placebo, with effects lasting through three days after a single dose.
That three-to-seven-day window is the main limitation of a single infusion. The antidepressant effect is real but temporary, which is why most treatment protocols now use a series of infusions rather than a one-time dose.
What a Typical Treatment Course Looks Like
The standard protocol involves intravenous ketamine at 0.5 mg/kg, infused over about 40 minutes. Most clinical courses start with a loading phase of roughly eight infusions over four weeks, administered twice per week. Some clinicians use doses up to 1.0 mg/kg for patients who haven’t responded to multiple prior treatments, though 0.5 mg/kg remains the most common starting point.
The antidepressant effects of repeated infusions appear to be cumulative, with symptoms decreasing after each session. In one study, participants who achieved a 50% reduction in depression scores after the initial loading phase then received weekly maintenance infusions, which were enough to sustain those improvements. The general strategy for maintenance involves gradually spacing out infusions while transitioning to or continuing other treatments like mood stabilizers, oral ketamine, or psychotherapy.
At nine months of follow-up in a naturalistic study, about 46% of initial responders maintained their response with ongoing treatment. Overall response and remission rates at that point were around 80% and 79%, which is notable for a population that had already failed other treatments.
The Mania Question
This is the concern most people with bipolar disorder have, and reasonably so. Antidepressants carry a real risk of triggering manic or hypomanic episodes, which is why they’re used cautiously (or avoided) in bipolar depression. Ketamine works through an entirely different mechanism, and the clinical data on mood switching has been reassuring. In a Yale study of bipolar patients receiving ketamine and esketamine, no participants experienced mania or hypomania during the acute treatment phase.
That said, ketamine treatment for bipolar depression is always given alongside a mood stabilizer, not as a standalone therapy. The mood stabilizer likely provides a safety net against switching, and this combination is how every major study has been designed.
Effects on Suicidal Thinking
Bipolar disorder carries one of the highest suicide risks of any psychiatric condition, so ketamine’s rapid effects on suicidal ideation are particularly relevant. In an open-label trial, suicidal ideation dropped significantly within four hours of infusion, with reductions sustained across multiple treatments. Across all trials, large reductions in suicidal symptoms were observed after one or more infusions, though the statistical significance varied between studies. Importantly, no participants in any trial reported an increase in preexisting suicidal thoughts after receiving ketamine.
How It Works Differently Than Other Treatments
Most medications for bipolar depression target serotonin, norepinephrine, or dopamine systems. Ketamine works on glutamate, the brain’s primary excitatory signaling chemical. By temporarily blocking certain receptors, ketamine triggers a cascade that ultimately increases levels of a protein called BDNF, which helps brain cells form new connections. This process appears to rapidly restore communication in neural circuits that depression has disrupted, which explains both the speed of the effect and why it feels qualitatively different from traditional antidepressants to many patients.
Medications That May Reduce Effectiveness
Two commonly prescribed medications in bipolar disorder can blunt ketamine’s effects. Benzodiazepines (drugs like lorazepam and clonazepam used for anxiety and sleep) increase inhibitory brain signaling in a way that works against ketamine’s mechanism. Studies consistently show that higher benzodiazepine doses delay the time to response, shorten the antidepressant effect, and predict nonresponse. If you’re considering ketamine treatment and currently take a benzodiazepine, your provider will likely want to minimize or temporarily adjust that medication.
Lamotrigine, one of the most widely prescribed mood stabilizers for bipolar depression, may also interfere. Because lamotrigine reduces glutamate activity, it could theoretically oppose ketamine’s action, and two out of five studies found that it attenuated ketamine’s effects. The clinical relevance isn’t fully established, but it’s something worth discussing with a provider, particularly if you don’t respond to an initial course of ketamine while taking lamotrigine.
Regulatory Status
Esketamine (Spravato), a nasal spray form, is FDA-approved only for treatment-resistant depression in the general population. It has not been specifically approved for bipolar depression. The FDA’s own advisory committee flagged bipolar depression as a population needing further study. All ketamine use for bipolar depression is currently off-label, meaning it’s prescribed based on clinical evidence and physician judgment rather than a formal FDA indication. This doesn’t mean it’s experimental in the way an untested drug would be. It means insurance coverage can be inconsistent and access varies significantly depending on where you live and which clinic you use.
Intravenous ketamine for bipolar depression is typically administered at specialized ketamine clinics or academic medical centers. Costs for an infusion series without insurance coverage generally run into the thousands of dollars, which remains a significant barrier for many patients.